1093 / 1816
FRACTIONATION
The DBCG RT Skagen Trial 1
The French HYPOG-01 trial
R
Women ≥18 years
Operated for early breast
cancer with an indication for
loco-regional RT
All tumour bed boost as SIB
50 Gy / 25
fr, 5 weeks
40 Gy / 15
fr, 3 weeks
Primary endpoint: ipsilateral arm lymph oedema
Sec endpoints: other morbidities, PROMs, pattern of recurrences
Follow up yearly for 5 years then at 10 years
DBCG trial: open since 2015
Active in 6/7 DK centres and centres
in Norway, Germany, Belgium, Poland,
Slovenia and soon in Finland and
Australia/New Zealand. Now 1000 pts
accrued. Continues until 1012 pts
have 3 yr morbidity results.
PI: Birgitte Offersen
HYPOG-01 trial: open since 2016
Active in 6 centres now, a total of 28
French centres will start. Now ~ 100
pts accrued. Continues until 1012 pts
have 3 yr morbidity results.
PI: Sofia Rivera
Skagen Trial:
www.dbcg.dk, Nielsen et al 2016, Francolini et al 2017, Eldesoky et al 2017